ResMed Inc. (RMD)
NYSE: RMD
· Real-Time Price · USD
278.64
2.00 (0.72%)
At close: Oct 03, 2025, 3:59 PM
279.00
0.13%
After-hours: Oct 03, 2025, 06:00 PM EDT
0.72% (1D)
| Bid | 269.99 |
| Market Cap | 40.8B |
| Revenue (ttm) | 5.15B |
| Net Income (ttm) | 1.4B |
| EPS (ttm) | 9.64 |
| PE Ratio (ttm) | 28.9 |
| Forward PE | 25.33 |
| Analyst | Buy |
| Dividends | $2.72 |
| Ask | 280.5 |
| Volume | 456,658 |
| Avg. Volume (20D) | 1,003,309 |
| Open | 278.30 |
| Previous Close | 276.64 |
| Day's Range | 277.39 - 281.39 |
| 52-Week Range | 199.92 - 293.81 |
| Beta | 0.83 |
| Ex-Dividend Date | Aug 14, 2025 |
Analyst Forecast
According to 0 analyst ratings, the average rating for RMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsResMed Inc. is scheduled to release its earnings on
Oct 23, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+2.67%
ResMed shares are trading higher after the company...
Unlock content with
Pro Subscription
5 months ago
+10.14%
ResMed shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results. Also, Keybanc maintained an Overweight rating on the stock and raised its price target from $269 to $274.
1 month ago · seekingalpha.com
ResMed: A Dividend Opportunity In The MedTech Space As The Company GrowsFor my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business acquisiti...
